CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

RidinilazoleNeutral
AI Analysis

Summary

Summit Therapeutics divested its ridinilazole asset to AI Biopharma Biossil. The transaction represents a strategic divestiture of a clinical-stage asset.

Importance:5/10
Sentiment:
0.00
asset divestitureM&Aantibiotic
Related Companies

Read the original article

Published by yahoo_finance on July 14, 2026 11:20 AM

Read Original